Michael D. Pickard

4.8k citations
38 papers · 2.2k · 2 hit papers · h-index 18

Impact in

  • Oncology top 2%
    • Cutaneous Melanoma Detection and Management
    • CAR-T cell therapy research
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • Melanoma and MAPK Pathways
    • Ubiquitin and proteasome pathways

Papers in

    • Melanoma and MAPK Pathways 15
    • Ubiquitin and proteasome pathways 10
    • Protein Degradation and Inhibitors 7
    • Colorectal Cancer Treatments and Studies 11
    • Cancer Treatment and Pharmacology 4
    • Cutaneous Melanoma Detection and Management 3

Michael D. Pickard

36 papers receiving 2.1k citations

Michael D. Pickard's Hit Papers

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial 2018 · 675 citations
6750+2+5Years since publication200400600

Peers

Michael D. Pickard
Comparison fields: 5 of 85
  • Oncology 1.3k
  • Molecular Biology 1.6k
  • Cancer Research 224
  • Immunology 311
  • Computational Theory and Mathematics 196
Replace Frank Wu with:
Frank Wu United States
Ilsung Chang United States
Jan Willem B. de Groot Netherlands
Laurie Sherman United States
Jeff Sosman United States
Peter F. Lebowitz United States
Ivana Krajsová Czechia
Michael Millward Australia
Davide Zecchin Italy
Kari Kendra United States
Michael D. Pickard relative to Frank Wu United States Frank Wu's profile →
Citations per field
00.5×3.8×
Frank Wu · 1×
Citations per year

Countries citing papers authored by Michael D. Pickard

Since Specialization
Citations

This map shows the geographic impact of Michael D. Pickard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Pickard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Pickard more than expected).

Fields of papers citing papers by Michael D. Pickard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Pickard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Pickard. The network helps show where Michael D. Pickard may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael D. Pickard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael D. Pickard Line = papers co-authored together Michael D. Pickard links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Hit paper breakdown →
2018675
2
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Hit paper breakdown →
2018392
3 2006240
4 2015139
5 2020122
6 200694
7 201691
8 201961
9 201445
10 202030
11 201729
12 202123
13 200222
14 200320
15 201019
16 202019
17 201819
18 202017
19 202015
20 201915

About Michael D. Pickard

Michael D. Pickard is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Immunology and Organic Chemistry, having authored 38 papers that have together received 2.2k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (15 papers), Colorectal Cancer Treatments and Studies (11 papers), Ubiquitin and proteasome pathways (10 papers), Protein Degradation and Inhibitors (7 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer Treatment and Pharmacology (4 papers), Computational Drug Discovery Methods (3 papers) and Cutaneous Melanoma Detection and Management (3 papers). The work is most often cited by research in Oncology (1.3k citations), Molecular Biology (1.6k citations), Cancer Research (224 citations), Immunology (311 citations) and Computational Theory and Mathematics (196 citations). Michael D. Pickard has collaborated with scholars based in United States, Italy and Spain. Frequent co-authors include Paolo A. Ascierto, Reinhard Dummer, Claus Garbe, Mario Mandalà, Caroline Robert, Helen Gogas, Dirk Schadendorf, Keith T. Flaherty, Carmen Loquai and Gabriella Liszkay. Their work appears in journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics, Annals of Oncology, Blood and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact